MA49253A - Compositions solides pour administration orale - Google Patents

Compositions solides pour administration orale

Info

Publication number
MA49253A
MA49253A MA049253A MA49253A MA49253A MA 49253 A MA49253 A MA 49253A MA 049253 A MA049253 A MA 049253A MA 49253 A MA49253 A MA 49253A MA 49253 A MA49253 A MA 49253A
Authority
MA
Morocco
Prior art keywords
oral administration
solid compositions
compositions
solid
oral
Prior art date
Application number
MA049253A
Other languages
English (en)
Inventor
Simon Bjerregaard
Susanne Schéele
Andreas Vegge
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59070439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49253(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49253A publication Critical patent/MA49253A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA049253A 2017-06-09 2018-06-11 Compositions solides pour administration orale MA49253A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175131 2017-06-09

Publications (1)

Publication Number Publication Date
MA49253A true MA49253A (fr) 2020-04-15

Family

ID=59070439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049253A MA49253A (fr) 2017-06-09 2018-06-11 Compositions solides pour administration orale

Country Status (28)

Country Link
US (2) US11167014B2 (fr)
EP (1) EP3634468B1 (fr)
JP (1) JP7239495B2 (fr)
KR (1) KR20200015564A (fr)
CN (1) CN110769846A (fr)
AR (1) AR112015A1 (fr)
AU (1) AU2018280875A1 (fr)
BR (1) BR112019025769A2 (fr)
CA (1) CA3064677A1 (fr)
CL (1) CL2019003402A1 (fr)
CO (1) CO2019013047A2 (fr)
DK (1) DK3634468T3 (fr)
ES (1) ES2938050T3 (fr)
FI (1) FI3634468T3 (fr)
HR (1) HRP20230075T1 (fr)
HU (1) HUE060962T2 (fr)
IL (1) IL270812B2 (fr)
MA (1) MA49253A (fr)
MX (1) MX2019013965A (fr)
MY (1) MY197488A (fr)
PE (1) PE20200606A1 (fr)
PH (1) PH12019550249A1 (fr)
PL (1) PL3634468T3 (fr)
PT (1) PT3634468T (fr)
RS (1) RS64045B1 (fr)
SI (1) SI3634468T1 (fr)
TW (1) TWI797133B (fr)
WO (1) WO2018224689A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
MA53076B1 (fr) 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020130502A1 (fr) * 2018-12-21 2020-06-25 (주)휴온스 Composition pharmaceutique comprenant l'empagliflozine et la sitagliptine
BR112022000490A2 (pt) * 2019-08-07 2022-03-08 Novo Nordisk As Composição farmacêutica
JP2023502004A (ja) * 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
WO2023065231A1 (fr) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Administration orale d'agents thérapeutiques
WO2023123063A1 (fr) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Administration orale
EP4299052A1 (fr) * 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE60023841T2 (de) 1999-02-05 2006-05-24 Emisphere Technologies, Inc. Verfahren zur herstellung alkylierter salicylamide
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
JP2009531291A (ja) 2006-02-15 2009-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2662080C (fr) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag Procede de fabrication de snac (salcaprozate sodium)
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2008144346A2 (fr) 2007-05-18 2008-11-27 Bristol-Myers Squibb Company Structures cristallines des inhibiteurs de sglt-2 et procédés pour leur préparation
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
WO2010138535A1 (fr) 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Méthodes pour le traitement de diabète de type 2 chez des patients résistant à un traitement précédent avec d'autres médicaments anti-diabétiques employant un inhibiteur sglt2 et compositions associées
MX2012005365A (es) 2009-11-13 2012-05-29 Bristol Myers Squibb Co Formulaciones de tableta de liberacion inmediata.
ES2561658T3 (es) 2009-12-16 2016-02-29 Novo Nordisk A/S Derivados de GLP-1 con doble acilación
RU2600440C3 (ru) * 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012140117A1 (fr) 2011-04-12 2012-10-18 Novo Nordisk A/S Dérivés de glp-1 à double acylation
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN105188736A (zh) 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
CN106132985B (zh) 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
WO2017004623A1 (fr) * 2015-07-02 2017-01-05 Rani Therapeutics, Llc Préparations d'agent thérapeutique à administrer dans une lumière du tractus intestinal au moyen d'un dispositif d'administration de médicament avalable
WO2018096162A1 (fr) 2016-11-28 2018-05-31 Novo Nordisk A/S Insuline dégludec utilisée dans des conditions cardiovasculaires
WO2018096164A1 (fr) 2016-11-28 2018-05-31 Novo Nordisk A/S Insuline dégludec pour le traitement du diabète
US11673933B2 (en) 2016-11-28 2023-06-13 Novo Nordisk A/S Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
BR112022000490A2 (pt) * 2019-08-07 2022-03-08 Novo Nordisk As Composição farmacêutica

Also Published As

Publication number Publication date
WO2018224689A3 (fr) 2019-02-28
AU2018280875A1 (en) 2019-12-12
JP7239495B2 (ja) 2023-03-14
TW201904583A (zh) 2019-02-01
SI3634468T1 (sl) 2023-02-28
HUE060962T2 (hu) 2023-04-28
CL2019003402A1 (es) 2020-03-20
CO2019013047A2 (es) 2020-04-01
BR112019025769A2 (pt) 2020-06-30
EP3634468B1 (fr) 2022-12-14
IL270812B1 (en) 2023-09-01
ES2938050T3 (es) 2023-04-04
PL3634468T3 (pl) 2023-03-13
US20220016216A1 (en) 2022-01-20
US20200147179A1 (en) 2020-05-14
US11167014B2 (en) 2021-11-09
EP3634468A2 (fr) 2020-04-15
CN110769846A (zh) 2020-02-07
DK3634468T3 (da) 2023-02-06
RU2019139082A3 (fr) 2021-09-16
FI3634468T3 (fi) 2023-02-19
JP2020522559A (ja) 2020-07-30
HRP20230075T1 (hr) 2023-03-17
KR20200015564A (ko) 2020-02-12
RU2019139082A (ru) 2021-06-02
MY197488A (en) 2023-06-19
MX2019013965A (es) 2020-01-23
PH12019550249A1 (en) 2020-07-13
PE20200606A1 (es) 2020-03-10
IL270812A (en) 2020-01-30
IL270812B2 (en) 2024-01-01
WO2018224689A2 (fr) 2018-12-13
PT3634468T (pt) 2023-03-28
AR112015A1 (es) 2019-09-11
TWI797133B (zh) 2023-04-01
CA3064677A1 (fr) 2018-12-13
RS64045B1 (sr) 2023-04-28

Similar Documents

Publication Publication Date Title
MA49253A (fr) Compositions solides pour administration orale
IL279442A (en) Pharmaceutical preparations that include meloxicam
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
DK3529248T3 (da) Farmaceutiske sammensætninger
FR3027521B1 (fr) Compositions pour administration par voie orale
DK3244878T3 (da) Faste orale sammensætningsformer
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA49837A (fr) Compositions pharmaceutiques
GB201804548D0 (en) Pharmaceutical compositions
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
IL304109A (en) Pharmaceutical preparations containing spinamide
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
GB201808571D0 (en) Pharmaceutical compositions
MA49625A (fr) Compositions pharmaceutiques
GB201808567D0 (en) Pharmaceutical compositions
HUE056233T2 (hu) Ibuprofén készítmények közvetlen orális beadásra
DK2952207T3 (da) Oliebaserede farmaceutiske sammensætninger til oral indgivelse
ZA202003079B (en) Pharmaceutical compositions comprising safinamide
MA51010A (fr) Compositions de soins buccodentaires
GB201810109D0 (en) Pharmaceutical compositions
DK3558261T3 (da) Farmaceutiske sammensætninger omfattende safinamid
GB201810261D0 (en) New pharmaceutical compositions
GB201810265D0 (en) New pharmaceutical compositions
IT201600131819A1 (it) Preparazione per spray orale
ITUA20163341A1 (it) Beccuccio di idropulsore per igiene orale